HomeAI · summaries
Storia in 5 fonti
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Pembrolizumab regimens snag FDA nod for muscle-invasive bladder cancer
The FDA has approved two immunotherapy combination therapies for adults with muscle-invasive bladder cancer. Pembrolizumab (Keytruda, Merck) or pembrolizumab and…
- ·
medpagetoday.com
FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting
Perioperative Keytruda-Padcev for MIBC approved regardless of cisplatin eligibility
- ·
morningstar.com
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin…
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- ·
fiercepharma.com
Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca
The increasingly more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again. | The forever more popular combination of Padcev and…
- ·
benzinga.com
Pfizer, Astellas Expand PADCEV-Keytruda Label With FDA Nod In Bladder Cancer - Pfizer (NYSE:PFE)
FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.
- ·
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab…
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and…